Table 4.
Logistic regression analysis of systemic inflammation markers, pre‐treatment myosteatosis, and skeletal muscle radiodensity loss
| Odds ratio (95% CI) | P‐value | |
|---|---|---|
| Pre‐treatment myosteatosisa | ||
| mGPS | ||
| mGPS 0 | Reference | |
| mGPS 1–2 | 3.47 (1.29–9.32) | 0.01 |
| NLR | ||
| NLR ≤3 | Reference | |
| NLR >3 | 1.37 (0.63–2.99) | 0.43 |
| PLR | ||
| PLR ≤150 | Reference | |
| PLR >150 | 2.01 (0.82–4.94) | 0.13 |
| SMD loss ≥5%b | ||
| mGPS | ||
| mGPS 0 | Reference | |
| mGPS 1–2 | 1.26 (0.56–2.81) | 0.58 |
| NLR | ||
| NLR ≤3 | Reference | |
| NLR >3 | 1.65 (0.77–3.55) | 0.20 |
| PLR | ||
| PLR ≤150 | Reference | |
| PLR >150 | 2.13 (0.83–5.49) | 0.12 |
Bolded P‐values are those significant with a P < 0.05. CI, confidence interval; mGPS, modified Glasgow prognostic score; NLR, neutrophil–lymphocyte ratio; PLR, platelet–lymphocyte ratio; SMD, skeletal muscle radiodensity.
a
Model adjusted for age and body mass index.
b
Model adjusted for age, body mass index, residual disease after primary debulking surgery, and malignant ascites.